3/1/2023 | CV | Market Commentary: TPI Composites, Encore convertibles expand on debut; IG paper struggles; Novavax plunges
|
3/1/2023 | CV | Market Commentary: Morning Commentary: TPI Composites, Encore convertibles expand on debut; Novavax plunges
|
1/4/2023 | CV | Market Commentary: Convertibles well bid; Uber, Airbnb, Bill.com notes active; Novavax underperforms
|
12/28/2022 | CV | Novavax greenshoe exercised, ups 5% convertibles to $175.25 million
|
12/16/2022 | CV | Market Commentary: Novavax volatile outright, mixed on hedge; Guardant Health down; Exact Sciences up
|
12/16/2022 | CV | Market Commentary: Morning Commentary: Novavax convertible notes crumble on debut as broader equities sink
|
12/16/2022 | CV | New Issue: Novavax prices upsized $150 million five-year convertibles to yield 5%, up 25%
|
12/15/2022 | CV | Market Commentary: Novavax convertibles offering eyed, credit questioned; Airbnb active; Carnival lower
|
12/15/2022 | CV | Market Commentary: Morning Commentary: Novavax convertible notes offering eyed in otherwise quiet primary
|
12/14/2022 | CV | Market Commentary: Novavax on deck; iQIYI convertible notes drop ‘like a stone’; Uniti, Wolfspeed lower
|
12/14/2022 | CV | Novavax talks $125 million five-year convertible notes to yield 4.75%-5.25%, up 22.5%-27.5%
|
6/3/2022 | CV | Market Commentary: ConMed convertibles give back outright gains; Okta up post-earnings; Novavax below par
|
5/25/2022 | SP | New Issue: Morgan Stanley prices $1 million 10.6% fixed coupon autocalls on Novavax
|
1/20/2022 | SP | New Issue: GS Finance prices $2 million autocallable contingent coupon equity notes on Novavax
|
12/11/2021 | SP | New Issue: Morgan Stanley sells $815,000 contingent income autocallable securities on Novavax
|
10/7/2021 | CV | Market Commentary: Sea surges in active trade; Square, LendingTree add with shares; Golar maturity eyed
|
10/7/2021 | CV | Market Commentary: Morning Commentary: Novavax convertibles trade with higher shares; Insmed notes eyed
|
10/6/2021 | CV | Market Commentary: Convertibles activity muted; Western Digital notes trade down; Novavax convertibles flat
|
10/6/2021 | CV | Market Commentary: Morning Commentary: Convertibles trade mildly; Western Digital down; Novavax flat
|
10/4/2021 | CV | Market Commentary: Morning Commentary: Southwest Airlines moves in convertibles secondary; primary inactive
|
9/28/2021 | SP | New Issue: CS sells $1.14 million contingent coupon autocallable notes with upper threshold on stocks
|
7/8/2021 | SP | New Issue: Credit Suisse sells $1.94 million autocallable reverse convertibles on Novavax, Workhorse
|
7/8/2021 | SP | New Issue: HSBC sells $3.49 million autocallable barrier notes with step-up premium on four stocks
|
9/2/2020 | SP | New Issue: Goldman prices $1.2 million leveraged basket-linked notes on 20 stocks
|
7/20/2020 | CV | Market Commentary: LendingTree on tap; Colony Capital gains; American Airlines active; Novavax improves
|
6/25/2020 | CV | Market Commentary: PG&E mandatories in demand; Xeris Pharmaceuticals stock tanks on convertibles offering
|
6/15/2020 | CV | Market Commentary: Convertibles primary market quiet; Pioneer Natural, Southwest Airlines, Jazz volatile
|
1/22/2020 | CV | Market Commentary: Barclays synthetic on tap; BofA synthetic tied to Charter, Elanco equity units eyed
|
5/10/2019 | CV | Novavax adjusts conversion rate on 3.75% convertible notes due 2023
|
2/28/2019 | CV | Market Commentary: LivePerson oversubscribed, expands on debut; Applied Optoelectronics eyed; Novavax tanks
|
9/25/2018 | CV | Market Commentary: Convertibles market eyes CenterPoint Energy offering; Chesapeake Energy, Novavax active
|
1/11/2018 | CV | Market Commentary: Exact Sciences to price $500 million; market awaits Coupa; Wheeler adds on; AmTrust active
|
1/10/2018 | CV | Market Commentary: Coupa to price; Wheeler to add on; Sempra preferreds unmoved; AmTrust, Novavax soar
|
9/25/2017 | CV | Market Commentary: Air Transport, IAC/InterActive deals on tap; Marriott Vacations trades actively, better
|
9/25/2017 | DD | Market Commentary: Windstream gets a default notice; CRC, Denbury remain firm; Toys’ debt continues to trade up
|
7/25/2017 | CV | Market Commentary: Novavax loses ground; Pacira trial results disappoint; Medicines’ data positive, bonds flat
|
7/24/2017 | CV | Market Commentary: WebMD convertibles jump on KKR purchase news; Arconic results beat as bonds wane; Novavax up
|
7/18/2017 | CV | Market Commentary: Morning Commentary: Bellwether convertible issues in focus; DISH paper declines with stock
|
9/19/2016 | CV | Market Commentary: Convertibles quiet; Blackhawk drags outright, dollar neutral; PTC Therapeutics moves up
|
9/19/2016 | CV | Market Commentary: Morning Commentary: DepoMed’s convertibles trade just under 140; PTC Therapeutics poised to move up
|
9/16/2016 | CV | Market Commentary: Novavax plummets after failed trials: Intel up with stock on better guidance; Wheeler prices
|
9/16/2016 | CV | Market Commentary: Morning Commentary: Novavax plummets after failed trial for RSV vaccine candidate; Wheeler prices
|
2/25/2016 | CV | Market Commentary: Restoration Hardware drops on disappointing preliminary results; Chesapeake holds in
|
2/17/2016 | CV | Market Commentary: Planned Invacare deal looks cheap; Priceline 0.9% convertibles contract with higher shares
|
2/17/2016 | CV | Market Commentary: Morning Commentary: Planned Invacare looks cheap; Priceline 0.9% convertibles contract
|
2/5/2016 | CV | Novavax greenshoe exercised, lifts 3.75% convertibles to $325 million
|
2/3/2016 | CV | Market Commentary: Tesla Motors, LinkedIn holding in amid volatility; Illumina 0% convertibles slip below par
|
1/26/2016 | PP | Market Commentary: New, upsized Novavax gains on swap; energy unchanged despite higher oil, share prices
|
1/26/2016 | CV | Market Commentary: New, upsized Novavax gains on swap; energy unchanged despite higher oil, share prices
|
1/26/2016 | CV | Market Commentary: Morning Commentary: New Novavax notes trade up after upsizing, pricing beyond cheap end of talk
|
1/25/2016 | CV | New Issue: Novavax sells $300 million seven-year convertibles at 3.75%, up 22.5%
|
1/25/2016 | PP | Market Commentary: Novavax is year’s first new convertible, looks a few points cheap; Chesapeake down
|
1/25/2016 | CV | Market Commentary: Novavax is year’s first new convertible, looks a few points cheap; Chesapeake down
|
1/25/2016 | CV | Market Commentary: Morning Commentary: Planned Novavax is year’s first new convertible, looks a few points cheap
|
1/25/2016 | CV | Novavax to price $200 million seven-year convertible notes to yield 2.75%-3.25%, up 27.5%-32.5%
|
9/27/2013 | PP | Novavax greenshoe exercised for $100 million public offering of stock
|
9/24/2013 | PP | Novavax prices $86.96 million public offering of common stock at $3.14
|
10/23/2012 | PP | Novavax concludes $26.78 million stock sale with group of investors
|
10/2/2012 | PP | Novavax could raise $50 million through at-the-market stock offering
|
5/21/2012 | PP | Novavax completes $12.2 million direct stock offering with RA Capital
|
3/16/2010 | CVHY | Novavax files $150 million shelf registration for stock, preferreds
|
7/1/2009 | PP | New Issue: Novavax orchestrates $3 million registered direct offering of shares
|
4/29/2009 | CV | Novavax to retire $17 million of 4.75% convertibles, will pay 70% in cash, 30% in stock
|
3/31/2009 | PP | New Issue: Novavax to raise $11 million in direct offering of shares
|
7/29/2008 | PP | New Issue: Novavax arranges $18 million direct offering of units
|
6/18/2007 | PP | Novavax reduces conversion price on 4.75% convertible notes due 2009
|
11/22/2006 | CV | Novavax files $100 million shelf registration
|
11/15/2006 | BT | Novavax kept at sector perform by RBC
|
11/14/2006 | BT | Novavax: third-quarter net loss up, revenues slip to $1.2 million for the period
|
9/27/2006 | BT | Market Commentary: Nabi hires BofA, up after hours; Millennium off; BioSante dives 14.5%; BioCryst, Novavax gain
|
9/19/2006 | BT | Novavax starts preclinical testing of intranasal influenza vaccine
|
9/19/2006 | BT | Market Commentary: Novavax slips; GenVec steady; Cell Therapeutics drops 16%; ImClone off; Vasogen up 12%
|
9/7/2006 | BT | Market Commentary: New River falls over 10%; Cell Genesys loses 5% after-hours; Ligand, King up; Sinovac up 7%
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/15/2006 | BT | Market Commentary: Acadia gains; Shire, Barr, New River up on settlement; Novavax rises; Vasogen off
|
8/15/2006 | BT | Novavax upgraded to sector perform
|
8/14/2006 | BT | Novavax increases R&D spending on flu vaccine program, reports $6.4 million second quarter net loss
|
7/31/2006 | BT | Novavax begins pre-clinical testing for new avian flu drug
|
7/31/2006 | BT | Market Commentary: ImClone off 4%, Repligen soars; Viragen slides, Napo debuts up; Pozen gains; Novavax up 12.5%
|
7/27/2006 | BT | Market Commentary: Adams hit 4%; Conor slips after follow-on; Diomed pockets $10 million from PIPE; Oscient gains
|
7/26/2006 | BT | Novavax at underperform by RBC
|
7/26/2006 | BT | Market Commentary: DOV comes off highs; Neurocrine extends losses after hours; bird flu stocks fly; NicOx rises
|
7/24/2006 | BT | Market Commentary: Genitope falls 12%; Micromet off; Oscient up; DepoMed dives; Atricure off; Discovery Labs rises 10%
|
7/18/2006 | BT | Novavax virus-like particle vaccines demonstrate ability to protect against influenza strains
|
7/18/2006 | BT | Market Commentary: Tercica up 12%, Insmed rises 9%; Neurocrine closes weaker; Pharma Product up; New River deal emerges
|
7/13/2006 | BT | Market Commentary: Nastech loses 15% on FDA snub; Novavax retreats; Anadys moves up; Acadia slumps; Illumina lifted
|
6/8/2006 | BT | Market Commentary: AtheroGenics drops; Nastech up; Novavax, BioCryst decline; Sirna slides; Acadia off; XenoPort drops
|
5/24/2006 | BT | Market Commentary: Sirna, Minrad, AngioDynamics follow-on deals get off; bird flu vaccine names continue to climb
|
5/23/2006 | BT | Market Commentary: Sirna slides 8% ahead of reduced deal; Auxilium gains; Alnylam off; bird flu names up after hours
|
5/19/2006 | BT | Novavax, Esprit Pharma to co-develop new drug for female sexual desire disorder
|
5/19/2006 | BT | RBC rates Novavax at underperform
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/15/2006 | BT | Novavax revenues up 35%
|
5/10/2006 | BT | Market Commentary: Alnylam gains as bird flu names slip; AVI pushes vaccine names lower; Novacea ends flat on debut
|
4/12/2006 | BT | Market Commentary: Vanda, Targacept tank on debut; Omrix IPO in limbo; Novavax, KOS climb; Discovery soars after hours
|
3/22/2006 | PP | Market Commentary: Equinox Minerals stock surges on $30 million PIPE; CardioVascular BioTherapeutics raises $20 million
|
3/21/2006 | BT | Market Commentary: Novavax, Nastech buck uptrend in flu names; NitroMed exec exits applauded; BioMarin off on deals
|
3/21/2006 | PP | Market Commentary: Novavax stock slips on $38 million direct stock deal; Think Partnership pens terms for $26.5 million PIPE
|
3/21/2006 | BTPP | New Issue: Novavax secures $38 million from direct placement of stock
|
3/16/2006 | BT | Novavax receives $1 million in government funding for HIV/AIDS vaccine research
|
3/16/2006 | BT | Market Commentary: Novavax, Nastech flu names on a tear; BioMarin higher on trial; Elite bobs, Titan slips on PIPEs
|
3/14/2006 | BT | Market Commentary: PharmAthene going public via Siga merger; Corautus crashes, deal nixed; Novavax, Generex up
|
3/6/2006 | BT | Novavax, Bharat Biotech form alliance for pandemic flu vaccine
|
3/6/2006 | BT | Market Commentary: Cubist players hedging bets with puts; Insmed follow-on emerges; Elan up; Titan zooms; LifeCell up
|
3/1/2006 | BT | Novavax loss tightens to $11.2 million for 2005
|
3/1/2006 | BT | Market Commentary: Cepheid follow-on on deck; Akorn bags $19.4 million; Novavax results priced in; Exubera buoys Nektar
|
2/28/2006 | PP | Market Commentary: Advanced Life Sciences prepares to close $36 million PIPE; Antares to settle $10.9 million offering
|
2/28/2006 | BT | Novavax, PacificGMP form alliance for pandemic flu vaccine production
|
2/27/2006 | BT | Market Commentary: Novavax bags $20 million, up 12%; BioCryst, Generex, Gilead also take flight; Cerus deal emerges
|
2/27/2006 | PP | Market Commentary: Novavax's stock up 11.7% on $20 million direct deal; Avalon raises $7.25 million in stock offering
|
2/27/2006 | BTPP | New Issue: Novavax to close $20 million direct placement of shares
|
2/15/2006 | BT | Novavax to collaborate with University of Pittsburgh on influenza vaccine
|
12/23/2005 | BT | Novavax receives $8 million cash payment from Esprit for Estrasorb
|
12/22/2005 | BT | Market Commentary: AtheroGenics zooms on $1 billion pact with AstraZeneca; Regeneron rises 6%; BioCryst bounces 16%
|
12/21/2005 | BT | Market Commentary: Biopure bleeds off 13% after deal; MGI rises 11%; Sinovac up 8%; Novavax plunges 14% post close
|
12/21/2005 | BTCV | Novavax files $100 million shelf
|
12/5/2005 | BT | Rodman & Renshaw begins Novavax coverage
|
12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|
11/10/2005 | BT | Market Commentary: King Pharma off, Pain increases; ViroPharma falls on generic risk; Eyetech, OSI seesaw on merger
|
11/3/2005 | PP | Market Commentary: Javelin Pharma rakes in $32 million from stock offering; higher oil won't impact PIPEs, sellsider says
|
11/2/2005 | BTPP | New Issue: Novavax gets agreements for $18 million direct placement
|
11/2/2005 | BT | Market Commentary: Novavax stock slips 12.3% on $18 million direct placement; convertible biotech names mixed
|
11/2/2005 | PP | Market Commentary: Novavax raises $18 million in direct offering; Nymox grosses $13 million from stock deal
|
10/24/2005 | BT | Esprit Pharma acquires rights to Estrasorb from Novavax for $10 million
|
10/24/2005 | BT | Market Commentary: Roche, Gilead gain on flu talks; niche flu names higher as well; Schering, Wyeth, Pfizer watched
|
10/12/2005 | BT | Market Commentary: Vical falls 20% on PIPEs deal; Threshold, Dynavax off on stock sales; Pharma Product higher
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
9/13/2005 | BT | Market Commentary: Immunomedics up; OSI rebounds; Celgene retreats; Protein Design Labs, Novavax, Cephalon all up
|
7/5/2005 | BT | Market Commentary: Voyager plans IPO; Able Labs plunges; Mylan Labs launch seen; Boston Scientific up, J&J lower
|
7/5/2005 | BT | New Issue: Novavax concludes $4 million all-or-none financing
|
6/30/2005 | BT | Novavax launches 4 million share offering at $1 each, on a best efforts, all-or-none basis
|
7/19/2004 | CV | New Issue: Novavax sells $35 million 4.75%, up 17% convertible notes in private placement
|